August 2026
The inaugural edition. Once a month, this page logs what actually changed — in regulation, in published research, and in this site's own coverage — with the same hedging discipline as everything else here.
FDA's advisory committee takes up the compounding peptides
The Pharmacy Compounding Advisory Committee scheduled formal review of several nominated peptides — including compounds popular in wellness programs — at its late-July meetings. Committee recommendations feed FDA's decisions about which substances licensed pharmacies may compound; they are a step in the process, not a verdict. If you're in a compounded-peptide program, this is the machinery deciding what your pharmacy may prepare next year.
The full timeline on Regulatory WatchThe GLP-1 head-to-head era is here
With direct comparison data now published between the major weight-management peptides, 'which one is better' has partially graduated from forum speculation to trial evidence — a rare upgrade in this space. Our comparison pages walk the numbers with the usual caveats about averages.
Semaglutide vs. tirzepatide, honestlyGeneric liraglutide keeps arriving
The first GLP-1 with a meaningful generic pathway continues rolling out in the US — quietly becoming the affordability conversation inside an expensive drug class. Worth knowing before assuming the newest molecule is the only door in.
The honest liraglutide profileOn this site: the library grew to 48 full profiles, verified 2026-08-20
Every compound in the library now carries a full profile — mechanism, origin story, the actual research record, risks, legal channel, and the questions worth taking to a provider. That now includes the clinic-menu additions people actually encounter: blends, glutathione, HCG, NAD+, even bacteriostatic water — each graded with the same honesty. All were checked against public information this month, and each page states its verification date.
Browse the library